Private CAM Research Incentives Advocated By White House Commission
This article was originally published in The Tan Sheet
The White House Commission on Complementary & Alternative Medicine Policy's final report will suggest the federal government provide incentives to stimulate private sector investment in CAM research
You may also be interested in...
Botanical products should either conform to established monographs or be subjected to clinical trials that prove their safety and efficacy, health policy analyst Rowena Richter said at an IoM Committee meeting on U.S. consumers' use of complementary & alternative medicine held in Washington, D.C. June 30
An Agency for Healthcare Research & Quality report on the safety and efficacy of ephedra, commissioned by the National Institutes of Health, could be released as early as August 2002.
Senator Tom Harkin (D-Iowa) posed several questions to the White House Commission on Complementary & Alternative Medicine at their commencement meeting in Washington, D.C. July 13.